tbuckley/cabot-search huggingface dataset:
Alterations in Sarcoplasmic Reticulum and Angiotensin II Receptor Type 1 Gene Expression in Spontaneously Hypertensive Rat Hearts
Authors: Yoshihisa Arata, Eiichi Geshi, Akihiko Nomizo, Shuichi Aoki, Takashi Katagiri
Journal: Circulation (1999)

Left ventricular hypertrophy (LVH) is an adaptive change in response to hypertensive pressure overload. Some evidence indicates that the decrease in sarcoplasmic reticulum (SR) Ca2+-ATPase mRNA expression, which may contribute to a diastolic dysfunction of the heart, occurs in the experimental pressure overload model. Also, recent studies have demonstrated that angiotensin II (Ang II) and angiotensin II receptor type 1 (AT1) play important roles in LVH. The purpose of this study was to investigate the function of the SR and the role of AT1 in genetic hypertension in spontaneously hypertensive rats (SHR) at ages 10 and 18 weeks. In SHR, cardiac hypertrophy has already developed at 10 weeks of age. SR Ca2+-ATPase activity and mRNA expression were significantly lower in SHR than in Wistar-Kyoto rats (WKY). Plasma renin activity in SHR was unchanged compared with WKY, whereas the Ang II concentration in SHR was significantly higher than that in WKY. AT1 mRNA expression in SHR was similar to that in WKY. These results suggest that in the early stage of hypertension in SHR Ang II may stimulate hypertrophy in the cardiomyocytes through the AT1, which is not downregulated by a high concentration of Ang II. (Jpn Circ J 1999; 63: 367 - 372)
Annals Story Slam - The Wait
Authors: Linda Jara
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 March 2017Annals On Being a Doctor Story Slam - The WaitFREELinda JaraLinda JaraSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0030 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - The Wait "The Wait," by Linda Jara (Duration 5:12)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Current Author Address: Linda Jara; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 March 2017Volume 166, Issue 5Page: SS1 ePublished: 7 March 2017 Issue Published: 7 March 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Occult Primary
Authors: _ _
Journal: Journal of the National Comprehensive Cancer Network (2008)

Occult primary tumors, or cancers of unknown primary, account for 5% to 10% of all diagnosed cancers, and are manifested by a wide variety of clinical presentations, while conferring a poor prognosis for most patients. Even after postmortem examination, the primary tumor is not identified in 20% to 50% of patients. Multiple sites of involvement are observed in more than 50% of patients. Although certain patterns of metastases suggest possible primaries, occult primaries can metastasize to any site. In most patients, occult primary tumors are refractory to systemic treatments, and chemotherapy is only palliative and does not significantly improve long-term survival. However, special pathologic studies can identify subsets of patients with tumor types that are more responsive. Treatment options should be individualized for this selected group to achieve improved response and survival rates. Important updates for the NCCN guidelines include the additions of tables on tumor-specific markers and their staining pattern as well as analysis of undifferentiated carcinoma. For the most recent version of the guidelines, please visit NCCN.org
Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
Authors: Hiroyuki Takamatsu, Ryoichi Murata, Jianbiao Zheng, Martin Moorhead, Naoki Takezako, Shigeki Ito, Toshihiro Miyamoto, Kenji Yokoyama, Kosei Matsue, Tsutomu Sato, Toshiro Kurokawa, Hideo Yagi, Yasushi Terasaki, Kinya Ohata, Takashi Yoshida, Malek Faham, Shinji Nakao
Journal: Blood (2015)
A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma
Authors: Jeffrey Lee Wolf, David Siegel, Jeffrey Matous, Sagar Lonial, Hartmut Goldschmidt, Stefan Schmitt, Ravi Vij, Margarida De Malgalhaes-Silverman, Rafat Abonour, Muhammad Jalaluddin, Martha Li, Katharine Hazell, Priscille M. Bourquelot, Maria-Victoria Mateos, Kenneth C. Anderson, Andrew Spencer, Jean-Luc Harousseau, Joan Bladé
Journal: Blood (2008)
Risk Stratification and Prognostic Factors in Elderly AML Patients – Updated Results of 909 Patients Entered Into the Prospective AML96 Trial.
Authors: Christoph RÖllig, Walter E. Aulitzky, Heinrich Bodenstein, Martin Bornhäuser, Norbert Schmitz, Silke Soucek, Michael Kramer, Christian Thiede, Ulrich Schuler, Hannes Wandt, Gerhard Ehninger, Markus Schaich
Journal: Blood (2009)
Abstract P3-07-14: Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells
Authors: L Quayle, S Park, DP McDonnell, PD Ottewell, I Holen
Journal: Cancer Research (2017)

Abstract Novel therapeutic strategies to eliminate chemo-resistant tumour cells responsible for the development of secondary lesions are essential in order to prevent breast cancer relapse. We have developed an in vitro model system enabling isolation of a putative metastasis-initiating breast cancer cell sub-population with a mitotically quiescent, drug-resistant phenotype. We hypothesise that this population is able to utilise oestrogen-related receptor-alpha (ERR-α)-regulated oxidative lactate metabolism and that inhibition of this critical survival pathway will result in elimination of tumour cells that have survived anti-cancer therapies. Flow cytofluormetric monitoring of Vybrant® DiD retention identified a mitotically quiescent sub-population (~0.05%) in MDA-MB-231 human breast cancer cells grown under high glucose (11mM) conditions. DiD-retaining cells accumulated in the G2/M phase of the cell cycle and were shown to be non-senescent following cytochemical analysis of β-galactosidase activity. Cytotoxicity assays with doxorubicin (0.40μM for 72 hours) demonstrated increased survival in the quiescent fraction (40.76%) compared with the rapidly dividing bulk cell population (1.63%, P ≤ 0.0001). Isolated drug-resistant cells contained a sub-fraction (~1%) that was able to form new clonal populations following cessation of treatment. Mitotically quiescent cells were cultured under high glucose (11mM) or glucose-depleted conditions with high lactate (22mM) in the presence of ERR-α inhibitors Cpd29 (10μM) or XCT790 (10μM). Colony formation was completely eliminated in Cpd29- and XCT790-treated samples compared to untreated controls. Drug-resistant sub-clones were isolated from the quiescent population following 72 hours treatment with doxorubicin (0.40μM) and were cultured under glucose-depleted conditions with high lactate (22mM) in the presence of ERR-α inhibitors Cpd29 (10μM) or XCT790 (10μM). In both instances, colony formation was completely prevented. We provide the first evidence that blocking cellular energy production through inhibition of ERR-α regulated oxidative lactate metabolism can eradicate a chemo-resistant, quiescent breast cancer cell population. Our data suggest that ERR-α inhibitors may be used in combination with chemotherapy to eliminate minimal residual disease and reduce breast cancer recurrence. Citation Format: Quayle L, Park S, McDonnell DP, Ottewell PD, Holen I. Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-07-14.
Expression of C-Type Lectin-Like Molecule-1 (CLL-1) on Stem Cells Might Discriminate De Novo Acute Myeloid Leukemia from Acute Myeloid Leukemia Originating from Myelodysplastic Syndromes
Authors: Theresia M Westers, Monique Terwijn, Canan Alhan, Yvonne FCM van der Veeken, Claudia Cali, Angele Kelder, Anna van Rhenen, Gerrit Jan Schuurhuis, Gert J Ossenkoppele, Arjan A van de Loosdrecht
Journal: Blood (2008)
CLL Exosome-Derived Y RNA hY4 Induces TLR7/8-Mediated Inflammation and PD-L1 Expression in Monocytes
Authors: Franziska Haderk, Laura Llao Cid, Murat Iskar, Ralph Schulz, Maria Goebel, Jan Duerig, Stephan Stilgenbauer, Marc Zapatka, Peter Lichter, Martina Seiffert
Journal: Blood (2016)
Abstract P6-09-36: Tamoxifen resistance: EGFR expression in hormone receptor-positive and HER2 negative breast cancer
Authors: SY Bae, SJ Nam, SK Lee, SW Kim, JE Lee, JH Yu
Journal: Cancer Research (2017)

Abstract Purpose: Crosstalk between growth factor receptor tyrosine kinases (RTKs) and the estrogen receptor (ER) represents one of the most important mechanisms of endocrine resistance. EGFR and HER2 have been recognized as prominent factors associated with endocrine resistance. Most previous studies did not identify subgroups by HER2 overexpression and/or included breast cancer with HER2 overexpression. Accordingly, we analyzed HR positive (HR+) tumors without HER2 overexpression (HER2-). Methods: We analyzed the clinical data of 2,166 patients with HR+HER2- breast tumors, between January 2007 and July 2013.We included only patients who had endocrine therapy with tamoxifen. Immunostaining for EGFR was interpreted as positive when at least 10% of the tumor cells showed moderate to strong membrane staining. Results: EGFR expression (EGFR+) was present in 109 patients (5%). EGFR expression was significantly associated with more advanced stage and higher grades. In the univariate analyses, EGFR+ tumors were associated with poorer prognosis than EGFR- tumors (5-year DFS, EGFR+ vs. EGFR-, 91.2% vs. 96.6%, P &amp;lt;0.001; 5-year OS, EFGR+ vs EGFR-, 93.1 % vs. 99.4%, P &amp;lt; 0.001). In the multivariate analysis, EGFR+ tumors had a hazard ratio of 2.63 (95% CI 1.14 -6.05) for DFS. EGFR+ tumors had a hazard ratio of 8.8 (95% CI 2.68-132.25) for OS. Conclusion: EGFR expression could be prognostic factor in hormone receptor-positive and HER2 negative breast cancer, for tamoxifen resistance. Citation Format: Bae SY, Nam SJ, Lee SK, Kim SW, Lee JE, Yu JH. Tamoxifen resistance: EGFR expression in hormone receptor-positive and HER2 negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-36.
Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Associated with Chromosome 5 Abnormalities.
Authors: Gautam Borthakur, Guillermo Garcia-Manero, Stefan Faderl, Zeev Estrov, Srdan Verstovsek, Mary Hood, Hagop Kantarjian
Journal: Blood (2007)
Randomized Comparison of Primary Allogeneic Stem Cell Transplantation and Best Available Drug Treatment in Chronic Myeloid Leukemia.
Authors: Rudiger Hehlmann, Markus Pfirrmann, Andreas Hochhaus, Martin C. Müller, Jörg Hasford, Hans-Jochem Kolb, Hermann Heimpel, Dieter K. Hossfeld, Alois Gratwohl
Journal: Blood (2006)
Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
Authors: Lydia ROY, Jean-Claude Chomel, Joelle Guilhot, Agnes Guerci-Bresler, Martine Escoffre-Barbe, Stéphane Giraudier, Aude Charbonnier, Viviane Dubruille, Françoise Huguet, Hyacinthe Johnson-Ansah, Pascal Lenain, Shanti Amé, Gabriel Etienne, Franck E. Nicolini, Delphine Rea, Pascale Cony-Makhoul, Stephane Courby, Jean-Christophe Ianotto, Laurence Legros, Martine Delain, Valérie Coiteux, Eric Hermet, Martine Gardembas, Mathieu Molimard, Jean-Michel Cayuela, Marie Thibaud, Sophie Duranton, Francois-Xavier Mahon, Philippe Rousselot, Francois Guilhot
Journal: Blood (2015)
Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Authors: Furqan Shaikh, John W. Cullen, Thomas A. Olson, Farzana Pashankar, Marcio H. Malogolowkin, James F. Amatruda, Doojduen Villaluna, Mark Krailo, Deborah F. Billmire, Frederick J. Rescorla, Rachel A. Egler, Bryan J. Dicken, Jonathan H. Ross, Marc Schlatter, Carlos Rodriguez-Galindo, A. Lindsay Frazier
Journal: Journal of Clinical Oncology (2017)

Purpose To investigate whether event-free survival (EFS) can be maintained among children and adolescents with intermediate-risk (IR) malignant germ cell tumors (MGCT) if the administration of cisplatin, etoposide, and bleomycin (PEb) is reduced from four to three cycles and compressed from 5 to 3 days per cycle. Patients and Methods In a phase 3, single-arm trial, patients with IR MGCT (stage II-IV testicular, II-III ovarian, I-II extragonadal, or stage I gonadal tumors with subsequent recurrence) received three cycles of PEb. A parametric comparator model specified that the observed EFS rate should not be significantly < 92%. As recommended for trials that test a reduction of therapy, a one-sided P value ≤ .10 was used to indicate statistical significance. In a post hoc analysis, we also compared results to the EFS rate of comparable patients treated with four cycles of PEb in two prior studies. Results Among 210 eligible patients enrolled from 2003 to 2011, 4-year EFS (EFS4) rate was 89% (95% confidence interval, 83% to 92%), which was significantly lower than the 92% threshold of the comparison model ( P = .08). Among 181 newly diagnosed patients, the EFS4 rate was 87%, compared with 92% for 92 comparable children in the historical cohort ( P = .15). The EFS4 rate was significantly associated with stage (stage I, 100%; stage II, 92%; stage III, 85%; and stage IV, 54%; P < .001). Conclusion The EFS rate for children with IR MGCT observed after three cycles of PEb was less than that of a prespecified parametric model, particularly for patients with higher-stage tumors. These data do not support a reduction in the number of cycles of PEb from four to three. However, further investigation of a reduction in the number of cycles for patients with lower-stage tumors is warranted.
In vitro and in vivo evaluation of human satellite muscle stem cells
Authors: Chiara Dell Agnola, Cristina Rabascio, Patrizial Mancuso, Manuela Capillo, Alberto Gobbi, Silvia Monestiroli, Nicoletta Tradati, Luca Calabrese, Massimo Corsaro, Sara Volorio, Giovanni Martinelli, Francesco Bertolini
Journal: Blood (2000)
Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Aggressive Non-Hodgkin Lymphoma: An Interim Analysis of a Phase I/II Study
Authors: Wolfgang A Bethge, Stephanie von Harsdorf, Martin Bornhauser, Dietrich Beelen, Matthias Stelljes, Rainer Schwerdtfeger, Lutz Uharek, Birgit Federmann, Christoph Faul, Wichard Vogel, Helmut Dittmann, Lothar Kanz, Donald Bunjes
Journal: Blood (2008)
Mutational Analysis for IDH1 and IDH2 In Pediatric Leukemia
Authors: Mitsuteru Hiwatari, Kentaro Oki, Jyunko Takita, Riki Nishimura, Masashi Sanada, Jun Okubo, Masatoki Adachi, Manabu Sotomatsu, Akira Kikuchi, Takashi Igarashi, Yasuhide Hayashi, Seishi Ogawa
Journal: Blood (2010)
Phase II, multicenter, open-label, proof of concept study of tasquinimod in patients with advanced/metastatic hepatocellular (HCC), ovarian (OC), renal cell (RCC) and gastric (GC) carcinomas.
Authors: Bernard J. Escudier, Sandrine J. Faivre, Amit M. Oza, Eric Van Cutsem, Geniaux Agnes, Frederique Baton
Journal: Journal of Clinical Oncology (2013)

TPS2622 Background: Treatment resistance and disease progression are common in HCC, OC, RCC and GC. Tasquinimod is an oral, quinoline-3-carboxamide derivative that binds to S100A9, resulting in immunomodulatory, anti-angiogenic and anti-metastatic effects involving downregulation of chemokine receptor type 4 and hypoxia-inducible factor. Tasquinimod significantly improves PFS (7.6 v 3.3 mo) in patients with metastatic hormone-resistant prostate cancer (Pili, R. et al. 2011. JCO 29:4022-8) and is in an ongoing phase III program. Its unique mode of action (MOA) makes tasquinimod attractive for other indications. The primary study objective is to determine the clinical activity of tasquinimod in advanced/metastatic HCC, OC, RCC and GC. Tasquinimod has been shown to delay disease progression with limited tumor shrinkage, therefore an innovative design was proposed, with PFS rate as the main endpoint. Methods: Design: Phase II, multinational, exploratory proof of concept study to evaluate tasquinimod activity in 4 independent cohorts of patients (HCC, OC, RCC and GC) with progressive disease after standard therapy. An innovative design (Litwin S. 2007. Stat Med 26:4400-15) based on the proportion of patients who have not progressed nor died at predefined timepoints (PFS rate) will be used in each cohort independently. Patients: 110–200 patients (dependent on outcome of futility analyses) aged ≥18 yr, ECOG performance status 0 or 1 will be enrolled. Patients must have histologically confirmed and documented HCC, OC, RCC or GC and demonstrable disease progression on standard therapy. Recruitment is ongoing. Dosage: Tasquinimod will be administered as a starting dose of 0.5 mg/day, in each cohort. After 2 wks, the dose will be increased to 1 mg/day based on individual safety and tolerability. Primary endpoint: PFS rate, defined as the proportion of patients who have neither progressed nor died at 12 wks (GC), 16 wks (HCC, RCC) or 24 wks (OC). Secondary endpoints: Include OS, response rate, safety, pharmacokinetics, inflammatory and specific target biomarkers to explore comprehensively the MOA according to each disease type. Clinical trial information: NCT01743469.
Direct Visualization of PR1/HLA-A2 on the Membrane of HLAA2+ CD13+CD33+ Myeloid Leukemia Blasts by a Novel Monoclonal Antibody
Authors: Anna Sergeeva, Sijie Lu, James N Wygant, Gheath Alatrash, Kathryn Quintanilla, Jeffrey J. Molldrem
Journal: Blood (2008)
Correct Data and Meta-analytic Approaches Show the Reduced Risk of Concussion for Athletes Playing at Higher Altitudes
Authors: Julian E. Bailes, David Smith
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Coffee Drinking and Alcoholic and Nonalcoholic Fatty Liver Diseases and Viral Hepatitis in the Multiethnic Cohort
Authors: Veronica Wendy Setiawan, Jacqueline Porcel, Pengxiao Wei, Daniel O. Stram, Nabil Noureddin, Shelly C. Lu, Loïc Le Marchand, Mazen Noureddin
Journal: Clinical Gastroenterology and Hepatology (2017)
Late Viral Infections After Cord Blood Transplantation: Comparison with Unrelated Bone Marrow Transplantation
Authors: Yuki Asano-Mori, Hiroshi Shimazu, Kazuya Ishiwata, Nobuaki Nakano, Masanori Tsuji, Hisashi Yamamoto, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Shuichi Taniguchi
Journal: Blood (2010)
Ultra-Deep Next-Generation Sequencing Detects RUNX1 Mutations with Unprecedented Sensitivity and Allows to Monitor Minimal Residual Disease In 116 Samples From MDS and AML Patients
Authors: Alexander Kohlmann, Vera Grossmann, Sonja Schindela, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, Susanne Schnittger
Journal: Blood (2010)
Perception of problems driving and driving simulator performance in obstructive sleep apnoea syndrome (OSAS)
Authors: Dipansu Ghosh, Samantha L. Jamson, Paul D. Baxter, Mark W. Elliott
Journal: European Respiratory Journal (2011)

Introduction: Advising patients with OSAS about driving is difficult. In the absence of an objective test reliance has to be given to a patient's account of their driving ability. In simulated driving, OSAS patients perform worse than controls but an individual's performance does not correlate with severity or symptoms of OSAS. Patients' account is also likely to be influenced by worry of losing licence. The relationship between patients' perception & driving simulator performance was explored as part of development of an advanced office based driving simulator (MiniSim) for patients with OSAS.

Methods: 72 patients (ESS 12±6,ODI 39±21) completed a questionnaire pertaining to their driving behaviour & completed 50 minutes of simulated motorway driving. Two events were programmed that required evasive action to avoid a crash;minor & major. A “fail” was defined by an unprovoked crash or crash at the minor event. A crash at the major event was deemed as “indeterminate”, the rest were deemed to have “passed”. Chi squared test was performed to see whether patients admitted to problem driving were more likely to “fail”.Logistic regression analysis was performed to predict a “fail” from the questionnaire.

Results: 54% subjects admitted to problem driving. Only the ESS was higher in these patients (p=0.0001). A “fail” could not be predicted from the questionnaire. Subjects who reported problem driving were not significantly more likely to fail than others. This highlights that patients' perceptions are not a reliable indicator of driving ability in OSAS. An objective test that is credible, reliable and practicable for everyday clinical use is needed to inform decision making.
Induction of Complete Remission with 5-Azacytidine in a Patient with Acute Myeloid Leukemia Refractory to Intensive Chemotherapy.
Authors: Andrea Kuendgen, Thorsten Graef, Sabine Knipp, Barbara Hildebrandt, Akos Czibere, Ali N. Huenerlituerkoglu, Ulrich Germing, Rainer Haas, Norbert Gattermann, Guido Kobbe
Journal: Blood (2005)
Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
Authors: Irene M. Ghobrial, Edie Weller, Ravi Vij, Nikhil C. Munshi, Ranjit Banwait, Meghan Rourke, Robert L. Schlossman, Jacob P. Laubach, Andrzej J Jakubowiak, Renee Leduc, Stacey Chuma, Janet Kunsman, Akari M. Dollard, Diane Warren, Brianna Harris, Tiffany Poon, Amy Sam, Scott J Rodig, Kenneth C. Anderson, Paul G Richardson
Journal: Blood (2010)
Phase II–III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial
Authors: Sergio Amadori, Stefan Suciu, Dominik Selleslag, Giuliana Alimena, Liliana Baila, Vittorio Rizzoli, Giuseppe Rossi, Gianluca Gaidano, Domenico Magro, Giuseppe Torelli, Petra Muus, Adriano Venditti, Emma Cacciola, Francesco Lauria, Filip Beeldens, Marco Vignetti, Theo de Witte
Journal: Blood (2008)